Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders .Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 24, 2021 | Post-IPO Debt | €3M | 1 | European Investment Bank | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Post-IPO Debt |